193 related articles for article (PubMed ID: 26823799)
1. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis.
Chen H; Zhang K; Wu G; Song D; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(11):14741-8. PubMed ID: 26823799
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
3. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
4. Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.
Zou MX; Huang W; Wang XB; Lv GH; Li J; Deng YW
Int J Clin Exp Pathol; 2014; 7(8):4877-85. PubMed ID: 25197358
[TBL] [Abstract][Full Text] [Related]
5. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.
Zhang K; Chen H; Wu G; Chen K; Yang H
Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803
[TBL] [Abstract][Full Text] [Related]
6. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
[TBL] [Abstract][Full Text] [Related]
7. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
8. Loss expression of PHLPP1 correlates with lymph node metastasis and exhibits a poor prognosis in patients with gastric cancer.
Wang Z; Shu H; Wang Z; Li G; Cui J; Wu H; Cai S; He W; He Y; Zhan W
J Surg Oncol; 2013 Dec; 108(7):427-32. PubMed ID: 24037758
[TBL] [Abstract][Full Text] [Related]
9. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.
Yang Y; Niu X; Li Y; Liu W; Xu H
Eur Spine J; 2017 Jul; 26(7):1910-1916. PubMed ID: 27942938
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
11. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma.
Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W
Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma.
Zhou J; Yu X; Wang J; Li T; Jin T; Lei D; Pan X
PLoS One; 2015; 10(3):e0119405. PubMed ID: 25793736
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.
Pan Y; Lu L; Chen J; Zhong Y; Dai Z
J Orthop Surg Res; 2018 Apr; 13(1):76. PubMed ID: 29625617
[TBL] [Abstract][Full Text] [Related]
15. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
[TBL] [Abstract][Full Text] [Related]
17. Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis.
Wen H; Ma H; Li P; Zheng J; Yu Y; Lv G
Biochem Biophys Res Commun; 2017 Sep; 491(4):1047-1054. PubMed ID: 28780352
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.
Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J
World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202
[TBL] [Abstract][Full Text] [Related]
19. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
20. Infections in surgery of primary tumors of the sacrum.
Ruggieri P; Angelini A; Pala E; Mercuri M
Spine (Phila Pa 1976); 2012 Mar; 37(5):420-8. PubMed ID: 22366943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
